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Abstract 
Background: Various microRNAs (miRNAs) negatively modulate genes that are involved in cellular proliferation, 
differentiation, invasion, and apoptosis. In many types of cancer, the expression profiles of these miRNAs are altered. 
Recently, miR-101 was identified as a tumour suppressor and was found to be expressed at low levels in various types 
of tumours, including prostate, breast, endometrium, and bladder cancers. However, the function(s) of miR-101 in 
laryngeal carcinoma remain unknown.
Methods: The expression levels of miR-101 in laryngeal squamous cell carcinoma (LSCC) tissues and cells were 
detected by qPCR. Cell proliferation, migration, cell cycle, and apoptosis assay were applied to assess the function(s) of 
miR-101 in vitro. Nude mice subcutaneous tumour model was used to perform in vivo study. Moreover, we identified 
Cyclin-dependent kinase 8 (CDK8) as the target of miR-101 by a luciferase assay. The possible downstream effectors of 
CDK8 were investigated in Wnt/β-catenin signaling pathway. Changes of CDK8, β-catenin, and cyclin D1 protein levels 
were analyzed by western blotting and immunohistochemical staining. The prognostic effect of miR-101 was evalu-
ated using the Kaplan–Meier method.
Results: Expression of miR-101 was down-regulated in the LSCC tissues compared with the adjacent normal tis-
sues. Furthermore, downregulation of miR-101 correlated with T3–4 tumour grade, lymph node metastasis, and an 
advanced clinical stage in the LSCC patients examined (P < 0.05). The low level of miR-101 expression was associ-
ated with poor prognosis (P < 0.05). CDK8 was identified as the target gene of miR-101 by luciferase reporter assay. 
Moreover, we showed that up-regulation of miR-101 expression suppressed humen LSCC Hep-2 cells proliferation 
and migration, and induced cell-cycle arrest. Increased expression of miR-101 induced cells apoptosis both in vitro 
and in vivo. Correspondingly, exogenous expression of miR-101 significantly reduced the growth of tumour in a LSCC 
xenograft model. Furthermore, the miR-101 level was inversely correlated with levels of CDK8, β-catenin, and cyclin 
D1 in western blotting assay and immunohistochemical staining assay.
Conclusions: These results indicate that miR-101 is a potent tumour repressor that directly represses CDK8 expres-
sion. Thus, detection and targeting of miR-101 may represent a novel diagnostic and therapeutic strategy for LSCC 
patients.
© 2015 Li et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Laryngeal malignancies are the second most common 
cancers of the head and neck, and more than 95  % of 
cases worldwide are diagnosed as laryngeal squamous 
cell carcinoma (LSCC) [1–3]. The incidence of LSCC is 
also higher in males than in females. According to the 
American Cancer Society, 12,720 new cases and 3,600 
deaths due to LSCC were estimated for the United 
States in 2010 [4]. Treatments for cancer of the larynx 
include surgery, radiotherapy, chemotherapy, or a com-
prehensive therapy approach. Despite improvements in 
diagnostic and therapeutic techniques, the 5-year sur-
vival rates for patients with LSCC have not increased 
over the last 20 years [5]. Most patients diagnosed with 
advanced-stage laryngeal cancer die of recurrence and/or 
metastasis. Thus, a better understanding of the molecu-
lar mechanisms involved in the carcinogenesis of LSCC 
would facilitate the development of much needed tar-
geted therapies.
MicroRNAs (miRNAs) are a family of small, single-
stranded, noncoding RNAs that bind target genes to neg-
atively regulate their expression by repressing translation 
and/or by causing mRNA degradation [6]. An estimated 
30  % of human mRNAs possess conserved miRNA-
binding sites [7]. A number of studies have shown that 
miRNAs contribute to many basic cellular functions 
including proliferation, differentiation and death [8–10]. 
Moreover, miRNAs have been found to play a critical 
role in tumourigenesis, either by serving as oncogenes or 
tumour suppressor genes [11–13]. Accordingly, dysfunc-
tion of specific miRNAs has been linked to tumourigen-
esis and cancer progression. [14, 15]. Thus, it is possible 
that some of these miRNAs may represent ideal targets 
for predicting and treating various cancers [16]. Recent 
studies have shown that some miRNAs are aberrantly 
expressed and involved in the regulation of the malig-
nant behavior of LSCC, such as cell invasion, metastasis 
and apoptosis [17–20]. These miRNAs may contribute 
to the elucidation of the molecular mechanisms involved 
in LSCC pathogenesis and the development of effective 
diagnostic methods and therapeutic strategies. A miRNA 
profiling using microarray analysis identified hsa-
miR-101 was down-regulated in head and neck cancers 
samples compared to normal samples [21], which inter-
ested us in the role miR-101 played in LSCC.
MiR-101 is a highly conserved miRNA, whose encod-
ing genes locate at chromosome 1p31.3 and chromosome 
9p24.1 and undergo abnormal deletions in several malig-
nant cells [22]. MiR-101 has been found to be frequently 
down-regulated in many types of tumours, including 
colon [23], prostate [24, 25], lung [26, 27], gastric [28], 
endometrium [29], breast [30], bladder [31, 32], mela-
noma [33], and head and neck squamous cell carcinomas 
[34]. Furthermore, miR-101 has been found to function 
as a tumour suppressor. Ectopic expression of miR-101 
significantly inhibits cell proliferation, migration, and 
invasion by regulating genes involved in these processes 
(e.g., COX-2 [23, 24, 28], EZH2 [25, 27–29, 33, 34], Mcl-1 
[28, 29], Fos [29], Stathmin1 [30] and c-Met [32]). How-
ever, the function(s) of miR-101 in laryngeal carcinoma 
remain unknown.
CDK8 is a member of the CDK family, involved in tran-
scriptional regulation from yeast to mammals [35, 36]. 
Currently, mechanisms for the regulation of CDK8 activ-
ity are not fully known. Most of what is known about 
CDK8 results from its facultative association with the 
Mediator complex, but functions alone are also likely 
[37–39]. A growing body of research provides unequivo-
cal evidence for CDK8 as coactivator in several transcrip-
tional programs. For example, CDK8 plays an important 
regulatory role in biological processes at the transcrip-
tion level in the Wnt/β-catenin signaling pathway and it 
is proposed to be a proto-oncogene in human colon can-
cer [40–42]. The computer sequence analysis (TargetScan 
and miRDB [7, 43]) suggested that the 3′ untranslated 
region (UTR) of CDK8 mRNA might represent a target 
of miR-101.
The purpose of this study is to explore the role of miR-
101 in LSCC cell proliferation, invasion, apoptosis and 
cell cycle regulation. Another goal is to investigate the 
underlying mechanism of miR-101 functions in LSCC. 
In this study, we found that miR-101 was down-regulated 
in LSCC cell lines and tissues. And miR-101 inhibited 
the tumourigenesis progression through the regulation 
of Wnt/β-catenin signaling pathway by targeting CDK8 
directly in LSCC. Therefore, our findings demonstrate 
the role of tumour suppressor of miR-101 in LSCC pro-
gression and indicate that miR-101 might serve as a prog-
nostic and therapeutic target for LSCC.
Methods
Samples
The patients who might have died for reasons other than 
the disease itself were excluded from the study. All of the 
80 patients who underwent partial or total laryngectomy 
at the Department of Otorhinolaryngology in the Second 
Affiliated Hospital of Harbin Medical University between 
2008 and 2009 were diagnosed with primary laryngeal 
squamous cell carcinoma by the pathologist. The tumour 
specimen was taken from the center of tumour tissue. 
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And the center of tumor tissue was the enrichment area 
of LSCC cells, which had been conformed by pathology. 
The adjacent normal tissues we used in this study were 
the tissues about 1.5–2  cm from the tumour border 
diagnosed without precancerous or cancerous lesion in 
pathology. Pairs of LSCC tissues and adjacent normal tis-
sues were collected during surgery and were immediately 
snap-frozen in liquid N2 for 5  min. Samples were then 
stored at −80  °C until processed. None of the enrolled 
patients received any preoperative therapy, and writ-
ten informed consent and clinicopathological data were 
obtained from all of the patients. The research protocol 
used was approved by the Ethics Committee of Harbin 
Medical University. (Approval number: 2013-041).
MiRNA expression assay
Total RNA was extracted from cells and tissues using Tri-
zol reagent (Invitrogen, Carlsbad, CA, USA) according to 
the manufacturer’s protocol. The RNA samples were then 
reverse transcribed into cDNA using an All-in-One™ 
miRNA Q-PCR Detection Kit (Genecopoeia, German-
town, MD, USA). Real-time PCR was performed using 
a SYBR-Green Master Mix (ABI, Foster, CA, USA) and 
a 7500 Fast Real-Time PCR system (Applied Bio-System, 
Foster City, CA). Reaction conditions included: 95 °C for 
10 min, followed by 40 cycles of 95 °C for 10 s, 57 °C for 
20 s, and 72 °C for 15 s. Expression data were calculated 
from the CT values and were normalized to expression 
of the human U6 gene in each sample using the 2−ΔCt 
method [44, 45]. Forward and reverse primers were 
used to detect has-miR-101 (5′-GAGGGGTACAGTA 
CTGTGATA-3′ and 5′-TGCGTGTCGTGGAGTC-3′, 
respectively) and hsRNA-U6 (5′-GCTTCGGCAGCACA 
TATACTAAAAT-3′ and 5′-CGCTTCACGAATTTGCGT 
GTCAT-3′, respectively) (Genechem, Shanghai, China). 
Each sample was measured in triplicate.
Luciferase reporter assays
The human wild CDK8 3′ untranslated region (UTR) 
(base 92–99, 5′-GUACUGUA-3′) was amplified 
and cloned into the multiple cloning sites in a psi-
CHECKTM-2 luciferase miRNA expression reporter 
vector (Promega). Site-directed mutagenesis of the miR-
101 target site in the CDK8-3′-UTR (5′-AUGCGGCA-3′) 
was used as a negative control and termed CDK8-
3′UTR mutant. The primers selected were as follows: 
CDK8-3′UTR, 5′-ATGCACTGTTGCGAATGCTG-3′ 
(forward) and 5′-AATGCTTGCCCCTAGCACAT-3′ 
(reverse); CDK8-3′UTR mutant, 5′-GAGAATATGCGG 
CAACAACC-3′ (forward) and 5′-GGTTGTTGCCGC 
ATATTCTC-3′ (reverse). For the reporter assays, cells 
were transiently transfected in 24-well plates with lucif-
erase reporter gene constructs and has-miR-101, or an 
antagomir that was designed to target endogenous has-
miR-101, using Lipofectamine 2000 (Invitrogen). Fire-
fly and Renilla luciferase activities for each transfected 
well were measured 48  h after transfection using dual 
luciferase assay reagents (Promega). Three independent 
transfection experiments were performed in triplicate for 
each plasmid construct.
Cell growth, transductions, and lentiviral production
The human LSCC cell line, Hep-2 (Cell Bank of Chinese 
Academy of Science, Shanghai, China), and the 16HBE 
cell line (Xiangfu Bio, Shanghai, China) were maintained 
in Dulbecco’s Modified Eagle’s Medium (DMEM; Ther-
moFisher Scientific, Waltham, MA) supplemented with 
10  % fetal bovine serum (FBS) (Shenggong, Shanghai, 
China) at 37 °C under a humidified atmosphere contain-
ing 5 % CO2. Has-miR-101 and a green fluorescent pro-
tein (GFP) sequence were cloned into a recombinant 
lentivirus vector (Genechem, Shanghai, China) (Addi-
tional file  1: Fig.  S1). Lentiviruses containing only the 
GFP cassette were used as a negative control. We named 
the lentivirus containing miR-101 sequence as miR-101 
lentivirus and the cells treated with miR-101 lentivirus as 
the miR-101-treated group; lentivirus containing only the 
GFP cassette as GFP-lentivirus and the cells treated with 
GFP-lentivirus as the negative control group; the cells 
without any treatment as the blank control group. Briefly, 
cells were seeded in 6-well plates (1  ×  105  cells/well). 
After 12 h, 1 ml of complete medium containing lentivi-
rus (108 TU/ml) and polybrene (8 mg/ml) were added to 
each well according to the manufacturer’s protocol. Cells 
were incubated at 37 °C for 12 h, then were incubated in 
DMEM medium containing 10 % FBS and 1 % penicillin–
streptomycin for an additional 24  h. Seventy-two hours 
after transduction, the infected cells were maintained in 
fresh DMEM and the mean percentage of GFP-positive 
cells present were calculated from three random fields-
of-view (FOV) per well using a fluorescence microscope 
(IX70, Olympus, Japan) at 200× magnification.
Animal experiments
Twenty-four healthy, 5-week-old, male BALB/c nude 
mice (~20  g each) were randomly divided into three 
groups (n  =  8 per group). Each mouse received a sub-
cutaneous injection of a Hep-2 cell suspension contain-
ing about 1 ×  106  cells (100 μl) into the dorsal scapula 
region. Tumour growth was subsequently measured 
twice a week and was calculated according to the follow-
ing formula: ½  ×  length  ×  width2. When the tumours 
reached a volume of ~0.5–0.6 cm3, the mice received var-
ious injections (injected into tumours) according to their 
treatment group. The mice in the treated group received 
an injection of miR-101 lentivirus (108  TU/ml, 100  µl) 
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once a week, the negative control mice received an injec-
tion of GFP-lentivirus (108 TU/ml, 100 µl) once a week, 
and the blank control mice received an injection of 100 µl 
DMEM once a week. After 4  weeks of these injections, 
the mice were sacrificed under ether anesthesia and the 
tumours were dissected for further analysis.
During the experimental period, the mice had free access 
to food and water and were maintained in sterile micro-
isolator cages under specific pathogen-free conditions at 
27 ±  1  °C and 50 ±  10  % humidity. The mice were also 
exposed to a 10-h lights on/14-h lights off cycle. Moreover, 
all BALB/c nude mice were under ether anesthesia before 
they were sacrificed. All animal handling and experimental 
procedures were performed in accordance with the guide-
lines of the Care and Use of Laboratory Animals published 
by the China National Institution of Health to ensure the 
implementation of the animal welfare measures.
Cell Counting Kit 8 (CCK8) cell proliferation assay
Cells were transfected and plated in 96-well plates 
(2  ×  103  cells/well). At various timepoints after trans-
duction (0, 24, 48, 72, and 96 h), 10 μL of CCK8 reagent 
(C0038, Beyotime Inst Biotech, China) was added to each 
well according to the manufacturer’s protocol. After the 
plates were incubated at 37  °C for 4  h, optical density 
values at 450  nm were measured for each well using a 
microplate reader (Multiscan MK3; Thermo Labsystems, 
USA). The average value for each set of five replicate 
wells for each group was calculated. The percentage rate 
of cell growth was calculated using the following formula: 
(mean absorbance of the treatment group/mean absorb-
ance of the control group) × 100.
Cell migration assays
Seventy-two hours after transduction, 200 μL of serum-
free medium containing 2 ×  104  cells from each group 
were added into the upper compartments of 24-well 
Boyden chambers (8 μm pore size) that had been coated 
with Matrigel (Becton–Dickinson Labware). In the lower 
compartment of each well, 1  ml of medium contain-
ing 10 % FBS served as a chemoattractant. After 24 h at 
37 °C, the cells on the top side of the filters were carefully 
removed, while cells that migrated to the bottom side 
of the filters were fixed with 4 % paraformaldehyde and 
stained with haematoxylin and eosin (H&E). Stained cells 
were observed at 200× magnification and were counted 
in five randomly selected non-overlapping fields to pro-
vide an average number of migrated cells. Three inde-
pendent experiments were performed.
Cell cycle assays
Seventy-two hours after transduction, cells were har-
vested by trypsinization, washed twice using cold PBS 
and fixed in 70 % ethanol at 4 °C. After 2 h, the cells were 
washed with PBS, were treated with RNase A (50 μg/ml), 
and were stained with propidium iodide (PI) (25 μg/ml) 
at 37 °C. After 30 min, 2 × 105 cells of each sample were 
analysed using a flow cytometer (FACS Calibur; Becton–
Dickinson Immunocytometry Systems, San Jose, CA, 
USA). The distribution of cells among the cycle phases 
was determined using Modfit software (LT for Mac, V 
3.0).
Apoptosis assay
Cell apoptosis was assessed using an Annexin V-FITC 
and PI double-stain detection kit (Key Gen Biotech, Nan-
jing, China) according to the manufacturer’s protocol. 
Briefly, cells were harvested 72 h after transduction and 
were resuspended in Annexin-binding buffer at a concen-
tration of 1 × 106 cells/mL. Cells were then stained with 
Annexin V-FITC and PI at room temperature in the dark. 
After 15 min, the cells were analysed by flow cytometry. 
The experiments were repeated in triplicate.
Apoptotic cells in tumour sections were detected by 
terminal deoxynucleotidyl transferase dUTP nick end 
labelling (TUNEL) using an In Situ Cell Death Detection 
Kit (R&D, USA). Briefly, after routine deparaffinization, 
sections were digested with a proteinase K solution for 
25  min, then were incubated with a blocking solution. 
After 15  min, the sections were incubated with 50  μL 
of a TUNEL reaction mixture for 60  min, then with an 
alkaline phosphatase antibody for 20 min. Diaminobenzi-
dine (DAB) was used as a chromogen to enhance positive 
signals. The slices were also counterstained with haema-
toxylin. Sections were then dehydrated and mounted. All 
incubations were performed at 37  °C under a humidi-
fied atmosphere. Negative controls were prepared by 
treating the samples without terminal deoxynucleotidyl 
transferase (TdT). To quantitatively analyse the data, 
the percentage of TUNEL-positive cells per 200 tumour 
cells were averaged from 10 randomly-selected FOV per 
section using light microscopy at 400× magnification 
(Olympus, Tokyo, Japan).
Western blotting
Cultured cells from the treated group, the negative con-
trol group, and the blank control group were harvested 
72 h post- transduction and were incubated with cell lysis 
buffer on ice. After 30 min, the cell lysates were separated 
by sodium dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE) in 10  % polyacrylamide gels and 
then were transferred to polyvinylidene fluoride (PVDF) 
membranes. Non-specific binding was blocked with a 
solution containing 5 % skim milk in Tris-buffered saline 
(TBS) containing 0.05  % Tween-20 (TBST). The mem-
branes were then incubated with primary antibodies 
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overnight at 4 °C. The primary antibodies used included 
rabbit anti-human CDK8 (1:200; Bioss, Beijing, China), 
rabbit anti-human β-catenin (1:200; Abbiotec, USA), and 
mouse anti-human cyclin D1 (1:200; Zhongshan Golden 
Bridge Biotechnology, Beijing, China). The membranes 
were subsequently washed with TBST and were incu-
bated with species-appropriate horseradish peroxidase-
conjugated secondary antibodies at 37  °C. After 1  h, 
the bands representing bound antibodies were quanti-
fied using Image J software (NIH, Bethesda, MD, USA). 
Detection of β-actin served as a loading control.
Immunohistochemistry
Formalin-fixed, paraffin-embedded samples were sec-
tioned (4  μm) sequentially. After deparaffinization and 
rehydration, the sections were treated with 0.3  % H2O2 
to quench endogenous peroxidase activity and then 
were blocked with 10 % normal goat serum for 20 min. 
Antigen retrieval was performed using ethylene diamine 
tetraacetic acid (EDTA) (pH 8.0) at 100  °C for 20  min. 
Each section was incubated with the appropriate primary 
antibody overnight at 4  °C. After a second incubation 
step at 37  °C for 45  min, sections were incubated with 
secondary antibodies at room temperature. After 1  h, 
peroxidase signal was developed by incubating sections 
with diaminobenzidine tetrachloride for 10 min. The sec-
tions were also counterstained with haematoxylin. Nega-
tive control sections were incubated with PBS instead of 
primary antibody.
Statistical analysis
Statistical analyses were performed using SPSS (version 
13.0). All values are expressed as the mean  ±  stand-
ard deviation (SD). Paired Student’s t-tests were used 
to determine the statistical significance of pairwise 
comparisons. Cell proliferation data were analyzed using 
two-tailed t tests. One way analysis of variance(ANOVA) 
followed by Student–Newman–Keuls (SNK)-q test was 
used to compare data from luciferase reporter assays, 
real-time PCR, cell cycle assays, invasion/migration 
assays, TUNEL assays, growth rates for LSCC xenografts 
and western blots. P values less than 0.05 were consid-
ered significant.
Results
Levels of miR‑101 in LSCC tissues and cell lines
Levels of miR-101 were ~fivefold higher in adjacent nor-
mal tissues than in cancer tissue (from the 80 patients) 
(P  <  0.05) (Fig.  1a). Similarly, higher level of miR-101 
was detected in the 16HBE cell line compared with the 
human LSCC cell line, Hep-2 (P < 0.05) (Fig. 1b). We also 
found no significant correlation between the expression 
of miR-101 and the tested clinicopathological param-
eters, which included the patient’s sex, age, differentia-
tion and tobacco exposure. However, the low miR-101 
expression was found to be correlated with higher-grade 
tumours, lymph node metastases, or more advanced clin-
ical stages of the gastric LSCC samples (P < 0.05, Table 1).
Prognostic significance of miR‑101 expression levels
There were 80 patients that were examined and 34 died 
during the follow-up period. The corresponding 5-year 
survival probability rates for these patients were 67.5 and 
47.5 % according to the expression levels of miRNA-101 
(e.g., high versus low, respectively) in the LSCC tissues 
examined (P  <  0.05) (Fig.  2). These results suggest that 
patients with LSCC tumours that express lower levels of 
miR-101 will have a poor prognosis and a shorter survival 
period compared with patients with LSCC tumours that 
express higher levels of miR-101.
Fig. 1 Expression of miR-101 in vivo and in vitro. a Levels of miR-101 that were detected in LSCC tissues were significantly lower than the levels of 
miR-101 detected in the corresponding adjacent, non-cancerous tissues. b Levels of miR-101 in the Hep-2 cells were significantly lower than in the 
16HBE cells. *P < 0.05.
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The 3′ UTR of CDK8 is a target for miR‑101
To test the hypothesis that the 3′ UTR of CDK8 is a func-
tional target of miR-101, the miR-101 seed sequence of 
the 3′ UTR of CDK8 was cloned into a luciferase reporter 
construct immediately downstream of the luciferase 
gene (Fig. 3a). In parallel, another reporter construct was 
generated which included a mutated version of the con-
served targeting region of miR-101 within the 3′-UTR 
of CDK8 (Fig.  3a). The relative luciferase activity of the 
reporter containing the wildtype 3′ UTR of CDK8 was 
significantly suppressed when miR-101 was co-trans-
fected (Fig. 3b). In contrast, the luciferase activity of the 
mutant reporter was unaffected by the simultaneous 
transfection of miR-101 (Fig. 3c).
Up‑regulation of miR‑101 in Hep‑2 cells reduces cell 
proliferation and induces cell cycle arrest
To investigate the biological function of miR-101 in 
LSCC, recombinant lentiviruses containing the human 
sequence of miR-101, as well as a GFP cassette, were gen-
erated to restore expression of miR-101 to a LSCC cell 
Table 1 Relationship between miR-101 expression levels and clinicopathological parameters for the present LSCC cohort
a Tumour/normal (T/N) ratio: fold change in miR-101 expression in LSCC tissue to the corresponding adjacent normal tissue. MiR-101 expression was measured by 
real-time PCR and was normalized to an external control (human U6 gene). Values were quantified using the 2−ΔΔCt method. Values are presented as the mean ± SD.
Clinicopathological parameters N (No. of patients) Level of miR‑101 expression (T/N ratio)a P value
Patient gender 0.776
 Male 56 0.208 ± 0.056
 Female 24 0.212 ± 0.059
T classification 0.015
 T1–2 40 0.225 ± 0.054
 T3–4 40 0.194 ± 0.055
Lymph node metastasis 0.044
 Negative 45 0.221 ± 0.051
 Positive 35 0.195 ± 0.06
Differentiation 0.096
 Well 54 0.202 ± 0.053
 Moderately/poorly 26 0.225 ± 0.061
Patient age 0.051
 ≥60 years 48 0.212 ± 0.050
 <60 years 32 0.206 ± 0.065
Clinical stage 0.004
 I–II 38 0.228 ± 0.054
 III–IV 42 0.192 ± 0.053
Tobacco exposure 0.638
 Smoker 60 0.208 ± 0.060
 Nonsmoker 20 0.215 ± 0.045
miR-101 levels <0.01
 Low 40 0.166 ± 0.030
 High 40 0.253 ± 0.039
Fig. 2 Kaplan–Meier overall survival (OS) curves for the LSCC cohort 
studied (n = 80). A significantly shorter 5-year OS rate was observed 
for patients with LSCC characterized by low levels of miR-101 expres-
sion (47.5 %; n = 40; lower curve) compared with LSCC patients with 
high levels of miR-101 (67.5 % %; n = 40; upper curve) (P = 0.047).
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line. Seventy-two hours after transduction, greater than 
80  % of Hep-2 cells in each set of the miR-101-treated 
group and the negative control group were found to 
express GFP, a marker of the infection efficiency of the 
lentivirus vectors (Additional file 2: Fig. S2 A-D). Corre-
spondingly, the expression level of miR-101 was up-reg-
ulated in the miR-101-treated cells compared with that 
in the negative control cells and the blank control cells, 
as measured by quantitative real-time PCR (P  <  0.05) 
(Additional file  2: Fig.  S2 E). Proliferation of the Hep-2 
cells was also measured following the transduction of 
lentivirus vectors. At various timepoints post- transduc-
tion (0, 24, 48, 72, and 96  h), the Hep-2 cells infected 
with the miR-101 lentivirus exhibited significantly less 
proliferation compared with the negative control cells 
(P < 0.05; Fig. 4B). To investigate the mechanism medi-
ating this antiproliferative effect, a cell cycle analysis was 
performed. The Hep-2 cells infected with the miR-101 
lentivirus showed an 8 % increase in the number of cells 
in the G0/G1 phase compared with the negative control 
cells (Fig. 4C).
MiR‑101 reduces invasion of Hep‑2 cells
To investigate the effect of miR-101 on the invasive phe-
notype of Hep-2 cells, invasion assays were performed 
using 24-well Boyden chambers coated with Matrigel. 
Fewer Hep-2 cells infected with the miR-101 lentivi-
rus migrated through the porous transwells 72  h after 
transduction (46.53 ± 6.71) compared with the negative 
control cells (70.07  ±  4.56) and the blank control cells 
(72.86 ± 6.36) (P < 0.05; Fig. 5). These data strongly sug-
gest that miR-101 negatively affects the invasive pheno-
type of LSCC cells.
MiR‑101 enhances the apoptosis of LSCC cells
As shown in Fig.  6A, the Hep-2 cells infected with the 
miR-101 lentivirus exhibited significantly higher levels 
of apoptosis (12.51  ±  2.22  %) 72  h after transduction 
Fig. 3 MiR-101 directly targets the 3′ UTR of CDK8 mRNA. a Wildtype and mutated miR-101 target sites in the 3′ UTR of CDK8 were cloned into lucif-
erase reporter vectors. b Luciferase activity for the wildtype CDK8 reporter significantly decreased by 43 % in HEK293T cells that expressed miR-101 
compared with the control cells (*P < 0.05). c Luciferase reporter gene assay for measuring interactions between miR-101 and 3′-UTR of the CDK8 
mutant in HEK293T cells. There was no significant difference between groups (P > 0.05). The luciferase experiments were repeated three times.
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than the blank control cells (4.12  ±  0.85  %) and the 
negative control cells (3.45 ±  1.39  %) (P  <  0.05). Apop-
tosis was also detected for the xenograft tumour model 
established in  vivo. For these studies, TUNEL assays 
were performed and significantly greater numbers of 
apoptotic cells were detected in the miR-101-treated 
Fig. 4 Exogenous expression of miR-101 reduces cell proliferation and induces cell cycle arrest in Hep-2 cells. A MiR-101 expression significantly 
increased in the miR-101-treated group compared with that in the negative control group and the blank control group in real-time RT-PCR 
assays (* P < 0.05). B Cell proliferation was reduced in the miR-101-treated group compared with the control groups 48, 72, and 96 h post-trans-
duction (P < 0.05). C Cell cycle profiles are shown for: Hep-2 cells in the blank control group (a) [G0/G1 = (64 ± 2.16) %, S = (28.94 ± 2.30) %, 
G2/M = (7.06 ± 1.40) %]; Hep-2 cells in the negative control group (b) [G0/G1 = (65.11 ± 1.05) %, S = (28.53 ± 1.14) %, G2/M = (6.36 ± 1.33) %]; 
and Hep-2 cells in the miR-101-treated group (c) [G0/G1 = (73.79 ± 2.45) %, S = (22.73 ± 1.05) %, G2/M = (3.47 ± 2.27) %].
Fig. 5 Exogenous expression of miR-101 reduces the migration of Hep-2 cells. Cell migration assays were performed 72 h after transduction using 
Boyden chambers coated with Matrigel. Fewer Hep-2 cells in the miR-101-treated group (c) migrated to the lower chambers of the transwell plates 
compared with the Hep-2 cells in the blank control group (a) and the Hep-2 cells in the negative control group (b). d Quantitation of the migration 
data ± SD is shown (*P < 0.05).
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group (27.07  ±  3.66  %) compared with the negative 
control group (5.73 ±  2.43  %) and blank control group 
(4.97  ±  2.14  %) (P  <  0.05; Fig.  6B). Furthermore, typi-
cal signs of apoptosis, such as nuclear condensation and 
fragmentation, marginalization of chromatin, cell shrink-
age, and formation of cytoplasmic vacuoles, were asso-
ciated with the miR-101-treated tumours (Fig.  6C, c). 
In contrast, tumour cells from the blank control group 
and the negative control group exhibited healthy char-
acteristics such as complete cellular structure, large and 
obvious nucleus, abundant chromatin, a mass of nuclear 
divisions, dual- nucleus or multi- nucleus phenomenons 
(Fig.  6C, a, b). Taken together, these data strongly indi-
cate that miR-101 induces apoptosis in LSCC cells.
MiR‑101 suppresses the growth of LSCC tumour xenografts 
in nude mice
Twenty-four mice were divided into three groups to 
establish xenograft tumour models. All of the mice 
formed detectable tumours during the experimental 
Fig. 6 Exogenous expression of MiR-101 enhances apoptosis by LSCC cells. A The Hep-2 cells in the miR-101-treated group (c) exhibited signifi-
cantly higher levels of apoptosis (12.51 ± 2.22 %) 72 h after transduction than the Hep-2 cells in the blank control group (a) (4.12 ± 0.85 %) and the 
cells in the negative control group (b) (3.45 ± 1.39 %) (P < 0.05). Representative histograms of the three independent experiments that were per-
formed are shown. B In the TUNEL assays performed, a significantly higher number of apoptotic cells were detected in the miR-101-treated group 
(c) (27.07 ± 3.66 %) compared with the negative control group (b) (5.73 ± 2.43 %) and the blank control group (a) (4.97 ± 2.14 %) (P < 0.05). C 
Using transmission electron microscopy, tumour cells in the miR-101-treated group (c) were found to exhibit a morphology characteristic of apop-
tosis, while tumour cells in the negative control group (b) and the blank control group exhibited normal morphology (a) (×12,000 magnification).
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period. However, the mean tumour volume for the 
mice treated with miR-101 lentivirus (0.34 ±  0.23  cm3) 
was much smaller than the tumour volumes recorded 
for the negative control group (0.82  ±  0.47  cm3) and 
the blank control group (0.89  ±  0.46  cm3). Similarly, 
the mean tumour weight for the mice treated with 
miR-101 lentivirus (0.41  ±  0.26  g) was markedly lower 
than the mean tumour weights for the negative con-
trol group (0.81  ±  0.50  g) and the blank control group 
(0.90 ± 0.51 g) (P < 0.05; Fig. 7).
MiR‑101 suppresses CDK8, beta‑catenin, and cyclin D1 
expression both in vitro and in vivo
The results of bioinformatic tools for miRNA target 
screening and luciferase assay indicated that miR-101 
interacted with CDK8. In addition, CDK8 has been found 
to affect the activity of β-catenin in human colon cancer 
[40–42]. As a result, we interested in whether miR-101 
could participate in the regulation of the Wnt/β-catenin 
signaling pathway through targetting CDK8 in LSCC. 
The expression levels of CDK8, β-catenin and down-
stream signalling molecules, cyclin D1, were measured 
in vitro and in vivo.
In vitro western blotting experiments, lower levels of all 
three proteins were detected in the miR-101-treated cells 
compared with the negative control and the blank control 
cells (P < 0.05) (Fig. 8A). Furthermore, the expression lev-
els of CDK8, β-catenin, and cyclin D1 were the same for 
the latter two cell groups (P > 0.05).
Immunohistochemical staining of tumour tissue sec-
tions was also performed to detect expression of CDK8, 
β-catenin, and cyclin D1 in vivo. Increased expression of 
all three proteins was observed in the tumours resected 
from the negative control mice and the blank control 
mice. In contrast, tumour sections from the miR-101-
treated mice exhibited only weak expression of cytoplas-
mic CDK8, β-catenin, and cyclin D1 (Fig. 8B).
Discussion
Accumulating evidence shows that alterations in miRNA 
expression levels can affect cell physiology and tumouri-
genesis in LSCC. For example, miR-129-5p has an onco-
genic role in LSCC and directly inhibits the tumour 
suppressor APC [19]. Consequently, miR-129-5p has 
been identified as a potential target for therapeutic inter-
vention in LSCC. Moreover, miR-203 is a tumour sup-
pressor identified in LSCC, and it is hypothesized to 
regulate ASAP1 in relation to epithelial–mesenchymal 
transition (EMT) and cancer stem cells [46]. These find-
ings demonstrate that miRNAs can have multiple roles in 
Fig. 7 MiR-101 inhibits the growth of LSCC in a xenograft tumour model. a The images of xenograft tumours in different treated groups. b Tumours 
in the miR-101-treated group had a smaller volume (cm3) than the tumours grown in the blank control group and the negative control group 
(P < 0.05). c The average tumour weight (g) for the miR-101-treated group was also lower than that for the blank control group and the negative 
control group.
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Fig. 8 Western blotting and immunohistochemical detection of CDK8, β-catenin, and cyclin D1. a Expression of CDK8, β-catenin, and cyclin D1 
in the cells of the miR-101-treated group were lower than the expression levels of these three proteins in cells of the blank control group and the 
negative control group (*P < 0.05). Detection of β-actin was used as a loading control. b Cytoplasmic labelling of CDK8, β-catenin, and cyclin D1 
in immunohistochemistry assays were weaker in tissues of the miR-101-treated group compared with the cells of the blank control group and the 
negative control group.
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LSCC, and the mechanistic details of these roles in rela-
tion to tumour progression remain to be determined.
Aberrant expression of miR-101 has been observed in 
several cancer cell lines and cancer tissues [23–34]. How-
ever, little is known about its pathophysiological roles 
versus its roles in the carcinogenesis of LSCC. In the 
present study, down-regulation of miR-101 was detected 
in LSCC tissues and not in matching normal tissues. 
Furthermore, exogenous expression of miR-101 led to a 
decrease in cell proliferation, reduced invasion of Hep-2 
cell lines, and reduced growth of a xenograft tumour 
in  vivo. To our knowledge, these data demonstrate, for 
the first time, that miR-101 functions as a tumour sup-
pressor in LSCC. Kaplan–Meier OS curves further 
showed that lower levels of miR-101 expression were 
associated with a shorter progression-free survival trend 
for patients with LSCC. Our results suggest that there is a 
potential role for miR-101 in the molecular pathogenesis, 
clinical progression and prognosis of LSCC.
The TargetScan and miRDB sequence analysis pre-
dicted that the 3′ UTR of CDK8 mRNA represented a 
target of miR-101. In the present study, it was confirmed 
that CDK8 is a direct target gene of miR-101 based on the 
use of wildtype and mutant 3′ UTR sequences of CDK8 
in luciferase reporter assays. In addition, the in vitro and 
in  vivo models evaluated in the present study showed 
that exogenous expression of miR-101 decreased expres-
sion levels of CDK8 expression.
CDK8 has been shown to be a coactivator of several 
important transcriptional programs, including the Wnt/
β-catenin pathway [40, 41], the p53 network [47, 48], the 
serum response network [49], and thyroid hormone-
dependent transcription [50]. This function is partially 
mediated by the CDK8/kinase module of the Media-
tor complex. Mediator is a large multisubunit complex 
composed of 25–30 proteins that plays a central role in 
the regulation of RNA polymerase II (Pol II) transcribed 
genes. The overall structure and function of the Media-
tor complex is conserved among mammals, and it is 
composed of four distinct modules: the head, middle, 
tail (representing the main complex core), and a CDK8/
kinase module [51–56]. Binding of the latter to the core 
of the Mediator complex prevents interactions between 
the Mediator complex and Pol II [56]. β-Catenin recruits 
Mediator complexes to β-catenin/T cell factor target 
genes in mammalian cells via its transactivation domain 
which interacts with the C-terminal domain of MED12 
[35]. Thus, CDK8 could directly activate β-catenin-
mediated transcription targets based on its role in the 
Mediator complex. However, there is also evidence that 
indicates that CDK8 can indirectly activate β-catenin-
dependent transcription targets by phosphorylating 
E2F1, an apoptosis activator, to inhibit its function [56, 
57]. In addition, CDK8 has emerged as an important 
regulator of cellular proliferation [58–61], cell cycle pro-
gression [62, 63], and cell differentiation [64, 65]. This 
regulation is partly mediated by the phosphorylation of 
histone H3 proteins [38, 39], the subunits of general tran-
scription factors [66, 67], and certain transactivators [68, 
69]. In the present study, the transduction of miR-101 
lentivirus led to a decrease in CDK8 expression and a 
decrease in β-catenin expression. However, the question 
whether miR-101-mediated regulation of CDK8 directly 
or indirectly affects Wnt/β-catenin signaling in LSCC 
remains. To elucidate this molecular mechanism, further 
studies are necessary in the future.
β-catenin is an important signaling molecule of Wnt/β-
catenin pathway that participates in both normal devel-
opment and tumourigenesis by regulating multiple 
aspects of cells, such as proliferation, migration, apop-
tosis, and differentiation [70–72]. Previously, we demon-
strated that miR-129-5p could regulate tumourigenesis 
progression in LSCC by regulating of the Wnt signalling 
pathway [19]. Interestingly, in this study, we found that 
exogenous miR-101 significantly decreased β-catenin 
protein expression and inhibited LSCC cell proliferation, 
invation, and induced apoptosis in  vitro and in  vivo. In 
addition, flow cytometric analysis showed that increased 
expression of miR-101 caused cell-cycle arrest at the 
G1/S border. Thus, we further investigated the effect of 
miR-101 on Wnt/β-catenin pathway. We found exog-
enous miR-101 not only could reduce β-catenin protein 
expression but could also concurrently decrease the Cyc-
lin D1 level in cultured Hep-2 cells and xenograft tissues. 
Cyclin D1 is an important promoter of the G1-S transi-
tion during the cell cycle, and is also an important tran-
scriptional target gene of the Wnt/β-catenin signalling 
pathway [73]. Therefore, our results revealed that indirect 
regulation of Wnt/β-catenin signalling pathway could be 
a potential mechanism of miR-101 inhibiting tumouri-
genesis progression of LSCC.
Taken together, the results of the present study sup-
port that miR-101-induced suppression of CDK8 expres-
sion down-regulates the expression of β-catenin either 
directly or indirectly to suppress Wnt/β-catenin signal-
ing. As a result, decreased expression of cyclin D1 occur. 
In LSCC cells, this would inhibit tumour progression, 
and this is consistent with the reduced proliferation and 
migration that were observed for Hep-2 cells expressing 
exogenous miR-101. The ability of miR-101 to negatively 
regulate tumour growth and progression was further 
demonstrated in  vivo when xenograft models of LSCC 
tumours exhibited slower growth following treatment 
with miR-101.
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Conclusion
In summary, the results of the present study verify that 
miR-101 is down-regulated in LSCC tumour tissues and 
exogenous expression of miR-101 inhibits cell prolif-
eration, reduces cell invasion, and induces apoptosis in 
LSCC. The present data also suggest that miR-101 directly 
inhibits the expression of CDK8 and down-regulates the 
protein level of β-catenin, with the latter involving the 
Wnt/β-catenin signaling pathway and the downstream 
effectors, cyclin D1. Thus, miR-101 appears to be a valu-
able target for the diagnosis and treatment of LSCC, and 
further study of this miRNA is warranted.
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